Foresight Pro Columns
HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Foresight™ Pro 45 cm inner diameter (ID) chromatography columns, designed to support downstream process-scale chromatography applications across different stages of biological drug production.
Expanding on Bio-Rad's portfolio of Foresight Pro columns with inner diameters ranging from 5 to 33 cm, the new, larger 45 cm ID Foresight Pro Column offers biopharma manufacturers an easily integrated solution for downstream purification of biomolecules, including vaccines, antibodies, and recombinant proteins. Foresight Pro Columns are manufactured and packed in a controlled ISO Class 7 cleanroom, providing good manufacturing practice (GMP) ready columns. The standardized design and format, in a range of diameters and bed heights, offer a convenient and reliable solution, packed with either CHT™ Ceramic Hydroxyapatite Media Type I, Type II, or XT. Bio-Rad’s CHT Media is a rigid mixed-mode support media for biomolecule purification. CHT’s unique composition, Ca10(PO4)6(OH)2, allows biomolecules to interact with the media by means of metal affinity interactions via calcium atoms and/or cation exchange interactions via phosphate groups.
"Building upon the successful reception of our initial range of 5 to 33 cm ID columns launched in 2022, the new 45 cm ID Foresight Pro Column is Bio-Rad's answer to customers' requests for larger columns," said Diab Elmashni, Director, Process Chromatography Business at Bio-Rad Laboratories. "These columns are unique in the market, as they are packed with a single lot of Bio-Rad's CHT Media — other suppliers may combine different batches of our resins when packing columns. Thus, Bio-Rad’s Foresight Pro Columns are unique, single-source solutions that provide superior technical, application, and product support benefits to the biopharmaceutical industry."
Visit bio-rad.com/ForesightPro45 for more information about Foresight Pro Columns.
Visit bio-rad.com/CHTmedia for more information about CHT Media and to request samples.
BIO-RAD, CHT, and FORESIGHT are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contacts:
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
+1 510-356-7909
Katrina_academia@bio-rad.com
Zyme Communications
Dr. Maria Spyrou
+44 (0) 7707 049 640
maria.spyrou@zymecommunications.com